XML 50 R39.htm IDEA: XBRL DOCUMENT
v3.19.1

Note 4 - Acquisitions (Details Textual) - USD ($) $ in Thousands |  |  | 8 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Aug. 01, 2018 | Jul. 02, 2018 | Mar. 31, 2019 | Mar. 31, 2019 | Mar. 31, 2019 | Mar. 31, 2019 | Mar. 31, 2018 | Feb. 01, 2018 | Jan. 02, 2018
Payments to Acquire Businesses, Net of Cash Acquired, Total |  |  |  | $ 272,286 |  |  | $ 65,066 |  |
QT Holdings Corporation [Member] |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired, Total |  | $ 20,404 |  |  |  | $ 20,461 |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |  | 51,000 | $ 51,000 | 51,000 | $ 51,000 | 51,000 |  |  |
Goodwill, Purchase Accounting Adjustments |  |  |  |  | 3,800 | 3,792 |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  | $ 20,000 | 12,200 | 12,200 | 12,200 | 12,200 |  |  |
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles |  |  |  |  |  | (7,800) |  |  |
Atlanta Biologicals [Member] |  |  |  |  |  |  |  |  |
Business Acquisition, Goodwill, Expected Tax Deductible Amount |  |  |  |  |  |  |  |  | $ 0
Exosome Diagnostics, Inc [Member] |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired, Total | $ 251,825 |  | 251,825 |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 325,000 |  | 325,000 | 325,000 | 325,000 | 325,000 |  |  |
Business Acquisition, Goodwill, Expected Tax Deductible Amount | 0 |  |  |  |  |  |  |  |
Goodwill, Purchase Accounting Adjustments |  |  | 13,474 |  |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Trade Names [Member] |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  | 58,000 | 58,000 | 58,000 | 58,000 |  |  |
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles |  |  | 58,000 |  |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Developed Technology [Member] |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 180,000 |  | 105,000 | 105,000 | 105,000 | 105,000 |  |  |
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles |  |  | (75,000) |  |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Customer Relationships [Member] |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  | 2,300 | $ 2,300 | 2,300 | 2,300 |  |  |
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles |  |  | 2,300 |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  | 14 years |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  | 15 years |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Calendar Year 2020 EBITA Between $45 Million and $58 Million or Greater [Member] |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 250,000 |  |  |  |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for A New Instrument Product Between $54 Million and $70 Million or Greater [Member] |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 45,000 |  |  |  |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for Remaining Business Between $150 Million and $190 Million or Greater [Member] |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 30,000 |  |  |  |  |  |  |  |
Eurocell Diagnostics, SAS [Member] |  |  |  |  |  |  |  |  |
Business Acquisition, Goodwill, Expected Tax Deductible Amount |  |  |  |  |  |  |  | $ 0 |
Goodwill, Purchase Accounting Adjustments |  |  | 13,500 |  |  |  |  |  |
Eurocell Diagnostics, SAS [Member] | Trade Names [Member] |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  | 58,000 | $ 58,000 | 58,000 | 58,000 |  |  |
Eurocell Diagnostics, SAS [Member] | Developed Technology [Member] |  |  |  |  |  |  |  |  |
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles |  |  | (75,000) |  |  |  |  |  |
Eurocell Diagnostics, SAS [Member] | Customer Relationships [Member] |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  | $ 2,300 | $ 2,300 | $ 2,300 | $ 2,300 |  |  |

X
- Definition The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 4A -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=SL65897772-128472 + Details
Name: | us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -URI http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillPurchaseAccountingAdjustments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_QTHoldingsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_AtlantaBiologicalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_ExosomeDiagnosticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tech_DevelopedTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=tech_CalendarYear2020EBITABetween45MillionAnd58MillionOrGreaterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=tech_CalendarYear2022EBITAForANewInstrumentProductBetween54MillionAnd70MillionOrGreaterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=tech_CalendarYear2022EBITAForRemainingBusinessBetween150MillionAnd190MillionOrGreaterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_EurocellDiagnosticsSASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |